Last reviewed · How we verify
Prasugrel loading
Prasugrel is a thienopyridine antiplatelet agent that irreversibly inhibits the P2Y12 adenosine diphosphate receptor on platelets, preventing platelet aggregation.
Prasugrel is a thienopyridine antiplatelet agent that irreversibly inhibits the P2Y12 adenosine diphosphate receptor on platelets, preventing platelet aggregation. Used for Acute coronary syndrome (ACS) including unstable angina, non-ST elevation myocardial infarction (NSTEMI), and ST elevation myocardial infarction (STEMI) managed with percutaneous coronary intervention (PCI).
At a glance
| Generic name | Prasugrel loading |
|---|---|
| Also known as | Effient |
| Sponsor | Azienda Policlinico Umberto I |
| Drug class | P2Y12 receptor antagonist (thienopyridine) |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Prasugrel is a prodrug that requires hepatic metabolism to form its active metabolite, which then binds irreversibly to the P2Y12 receptor on platelet surfaces. This blocks ADP-mediated platelet activation and aggregation, reducing thrombotic events. The loading dose is administered acutely to rapidly achieve antiplatelet effects in acute coronary syndrome patients.
Approved indications
- Acute coronary syndrome (ACS) including unstable angina, non-ST elevation myocardial infarction (NSTEMI), and ST elevation myocardial infarction (STEMI) managed with percutaneous coronary intervention (PCI)
Common side effects
- Bleeding (major and minor)
- Thrombotic thrombocytopenic purpura (TTP)
- Dyspnea
- Bradycardia
Key clinical trials
- Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion (PHASE4)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- The Elderly ACS II Trial (PHASE4)
- SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy (PHASE2)
- Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study (NA)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Comparing T-stenting And Minimal Protrusion With External Minicrush for Treatment of Complex Coronary Bifurcation
- Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prasugrel loading CI brief — competitive landscape report
- Prasugrel loading updates RSS · CI watch RSS
- Azienda Policlinico Umberto I portfolio CI